Acro Biomedical Co., Ltd.
ACBM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.56M
Close$
$-0.01
120.8% downside
Current Fair Value
120.8% downsideOvervalued by 120.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.56 Million |
|---|---|
| Enterprise Value | $1.94 Million |
| Earnings per Share | $0 |
| Beta | -2.38 |
| Outstanding Shares | 60,042,000 |
Return
| Return on Equity | 31.57% |
|---|---|
| Return on Assets | -3849.04% |
| Return on Invested Capital | 47.06% |
Valuation & Multiples
| P/E Ratio | -10.83 |
|---|---|
| PEG | -29.1 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.28 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | -0.87 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Acro Biomedical Co., Ltd.
1 employees
CEO: Jing Zhou Chen
Acro Biomedical Co., Ltd. focuses on the development and commercialization of dietary supplements. The company offers products such as cordycepin and powdered cordyceps, which come from a type of fungus traditionally utilized in Chinese ...